📊 NMRA Key Takeaways
Is Neumora Therapeutics, Inc. (NMRA) a Good Investment?
Neumora is a pre-revenue biotech company with a strong balance sheet ($147.1M cash) and approximately 3.2 years of cash runway at current burn rates. However, the absence of revenue, significant operating losses (-$52.9M), and negative cash flow (-$46.4M annually) mean the investment thesis depends entirely on unvalidated pipeline success with no fundamental profitability metrics to assess.
Neumora is pre-revenue with substantial operating losses (-$241M) and deeply negative returns, indicating no near-term path to profitability. Liquidity is solid (cash ~$183M; current ratio 5.9x), but burn (~-$206M OCF) suggests a short runway and dependence on external financing. Until there is tangible non-dilutive funding or revenue visibility from successful programs, fundamentals remain unfavorable.
Why Buy Neumora Therapeutics, Inc. Stock? NMRA Key Strengths
- Strong cash position of $147.1M provides substantial operating runway
- Excellent liquidity ratios (5.09x current ratio) with minimal near-term solvency risk
- Moderate leverage (0.75x debt/equity) with reasonable financial flexibility
- Minimal capital expenditure ($16.0K) suggests focused R&D without manufacturing burden
- Strong liquidity with $182.5M cash and 5.87x current ratio
- Minimal capex needs; spend focused on R&D
- Moderate leverage (0.52x D/E) with liabilities covered by cash
NMRA Stock Risks: Neumora Therapeutics, Inc. Investment Risks
- Pre-revenue stage with no revenue generation or path to profitability visible
- High annual operating burn of $46.4M will deplete cash reserves within 3-4 years if not addressed
- Negative ROE (-75.6%) and ROA (-34.7%) reflect value destruction without offsetting revenue
- Complete dependence on clinical trial success and future product commercialization for survival
- Interest coverage ratio of -36.8x indicates debt service sustainability concerns
- No revenue; persistent large operating and net losses
- High cash burn (-$206M OCF) implying limited runway and financing risk
- Interest coverage deeply negative (-120x) and typical clinical/regulatory execution risks
Key Metrics to Watch
- Cash burn rate trend and runway depletion timeline
- Operating loss trajectory and path to revenue generation
- Clinical trial progress and regulatory milestones for pipeline programs
- Debt refinancing or additional capital raise requirements and terms
- Cash runway (months of liquidity vs burn)
- Operating cash flow (TTM)
Neumora Therapeutics, Inc. (NMRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.09x current ratio provides a solid financial cushion.
NMRA Profit Margin, ROE & Profitability Analysis
NMRA vs Healthcare Sector: How Neumora Therapeutics, Inc. Compares
How Neumora Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neumora Therapeutics, Inc. Stock Overvalued? NMRA Valuation Analysis 2026
Based on fundamental analysis, Neumora Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neumora Therapeutics, Inc. Balance Sheet: NMRA Debt, Cash & Liquidity
NMRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neumora Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.53 indicates the company is currently unprofitable.
NMRA Revenue Growth, EPS Growth & YoY Performance
Neumora Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
NMRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neumora Therapeutics, Inc. (CIK: 0001885522)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NMRA
What is the AI rating for NMRA?
Neumora Therapeutics, Inc. (NMRA) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NMRA's key strengths?
Claude: Strong cash position of $147.1M provides substantial operating runway. Excellent liquidity ratios (5.09x current ratio) with minimal near-term solvency risk. ChatGPT: Strong liquidity with $182.5M cash and 5.87x current ratio. Minimal capex needs; spend focused on R&D.
What are the risks of investing in NMRA?
Claude: Pre-revenue stage with no revenue generation or path to profitability visible. High annual operating burn of $46.4M will deplete cash reserves within 3-4 years if not addressed. ChatGPT: No revenue; persistent large operating and net losses. High cash burn (-$206M OCF) implying limited runway and financing risk.
What is NMRA's revenue and growth?
Neumora Therapeutics, Inc. reported revenue of N/A.
Does NMRA pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
Where can I find NMRA SEC filings?
Official SEC filings for Neumora Therapeutics, Inc. (CIK: 0001885522) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NMRA's EPS?
Neumora Therapeutics, Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NMRA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Neumora Therapeutics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NMRA stock overvalued or undervalued?
Valuation metrics for NMRA: ROE of -75.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NMRA stock in 2026?
Our dual AI analysis gives Neumora Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NMRA's free cash flow?
Neumora Therapeutics, Inc.'s operating cash flow is $-46.4M, with capital expenditures of $16.0K.
How does NMRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -75.6% (avg: 15%), current ratio 5.09 (avg: 2).